Michael Wiederhorn
Stock Analyst at Oppenheimer
(4.78)
# 577
Out of 5,076 analysts
1102
Total ratings
58.5%
Success rate
11.2%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCSG Healthcare Services Group | Reiterated: Buy | $28 | $25.30 | +10.67% | 2 | Oct 22, 2026 | |
| HUM Humana | Reiterated: Buy | $405 → $475 | $422.07 | +12.54% | 81 | Oct 9, 2026 | |
| CI The Cigna Group | Reiterated: Buy | $365 | $306.95 | +18.91% | 76 | Oct 1, 2026 | |
| ENSG The Ensign Group | Reiterated: Buy | $210 | $175.59 | +19.60% | 89 | Sep 22, 2026 | |
| ASTH Astrana Health | Initiated Coverage: Buy | $53 | $37.45 | +41.52% | 1 | Sep 15, 2026 | |
| PACS PACS Group | Reiterated: Buy | $48 → $57 | $47.64 | +19.65% | 6 | Aug 10, 2026 | |
| EVH Evolent Health | Rated: Buy | $6 | $4.80 | +25.00% | 13 | Aug 7, 2026 | |
| GRDN Guardian Pharmacy Services | Reiterated: Buy | $43 → $49 | $39.44 | +24.24% | 8 | Aug 7, 2026 | |
| TDOC Teladoc Health | Rated: Buy | $7 | $6.34 | +10.41% | 31 | Aug 4, 2026 | |
| CHE Chemed | Rated: Buy | $500 → $590 | $512.98 | +15.01% | 118 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $520 → $485 | $469.03 | +3.40% | 96 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.92 | +36.99% | 121 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $405 → $500 | $418.09 | +19.59% | 88 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $41.88 | -4.49% | 18 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $155 | $121.81 | +27.25% | 113 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $58 | $70.17 | -17.34% | 163 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $93.47 | n/a | 17 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.0003 | n/a | 6 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $38.59 | n/a | 1 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $439.95 | n/a | 48 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $0.000001 | n/a | 6 | Aug 19, 2014 |
Healthcare Services Group
Oct 22, 2026
Reiterated: Buy
Price Target: $28
Current: $25.30
Upside: +10.67%
Humana
Oct 9, 2026
Reiterated: Buy
Price Target: $405 → $475
Current: $422.07
Upside: +12.54%
The Cigna Group
Oct 1, 2026
Reiterated: Buy
Price Target: $365
Current: $306.95
Upside: +18.91%
The Ensign Group
Sep 22, 2026
Reiterated: Buy
Price Target: $210
Current: $175.59
Upside: +19.60%
Astrana Health
Sep 15, 2026
Initiated Coverage: Buy
Price Target: $53
Current: $37.45
Upside: +41.52%
PACS Group
Aug 10, 2026
Reiterated: Buy
Price Target: $48 → $57
Current: $47.64
Upside: +19.65%
Evolent Health
Aug 7, 2026
Rated: Buy
Price Target: $6
Current: $4.80
Upside: +25.00%
Guardian Pharmacy Services
Aug 7, 2026
Reiterated: Buy
Price Target: $43 → $49
Current: $39.44
Upside: +24.24%
Teladoc Health
Aug 4, 2026
Rated: Buy
Price Target: $7
Current: $6.34
Upside: +10.41%
Chemed
Jul 31, 2026
Rated: Buy
Price Target: $500 → $590
Current: $512.98
Upside: +15.01%
Jul 27, 2026
Reiterated: Buy
Price Target: $520 → $485
Current: $469.03
Upside: +3.40%
Jul 24, 2026
Reiterated: Buy
Price Target: $4
Current: $2.92
Upside: +36.99%
Jul 17, 2026
Rated: Buy
Price Target: $405 → $500
Current: $418.09
Upside: +19.59%
May 8, 2026
Reiterated: Buy
Price Target: $40
Current: $41.88
Upside: -4.49%
May 6, 2026
Rated: Buy
Price Target: $155
Current: $121.81
Upside: +27.25%
Apr 29, 2026
Rated: Buy
Price Target: $45 → $58
Current: $70.17
Upside: -17.34%
Aug 9, 2024
Reiterated: Hold
Price Target: n/a
Current: $93.47
Upside: n/a
Mar 2, 2023
Reiterated: Buy
Price Target: $3
Current: $0.0003
Upside: n/a
Feb 9, 2018
Reiterated: Buy
Price Target: $35
Current: $38.59
Upside: n/a
Jun 7, 2017
Rated: Hold
Price Target: n/a
Current: $439.95
Upside: n/a
Aug 19, 2014
Rated: Buy
Price Target: $7
Current: $0.000001
Upside: n/a